RedHill’s Talicia Advances as Preferred H. pylori Treatment
Company Announcements

RedHill’s Talicia Advances as Preferred H. pylori Treatment

RedHill Biopharma (RDHL) has released an update.

RedHill Biopharma Ltd. has announced that its drug Talicia® is now recommended as a first-line treatment for H. pylori infections in the new American College of Gastroenterology guidelines, due to its high eradication rates and minimal antibiotic resistance. Talicia® offers a simplified treatment regimen, potentially improving patient outcomes and addressing antibiotic resistance concerns. The drug is also covered by U.S. patents extending protection until 2034, with additional international patents pending.

For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskRedHill Biopharma to Present Opaganib at U.S. Defense Conference
TipRanks Auto-Generated NewsdeskRedHill Biopharma and Duke Collaborate on Opaganib Development
TheFlyRedHill Biopharma signs research pact with Duke University School of Medicine
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App